Log in
Login
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Pluristem Therapeutics Inc.    PSTI

Delayed Quote. Delayed  - 07/22 10:00:00 pm
1.53 USD   +1.32%
07/20 Pluristem Participates in Radiation Injury Treatment Network Conf..
07/11 Pluristem Advances its U.S. FDA Trial in Hematologic Indication
06/22 Pluristem Reports Data Showing PLX-PAD Cells Effective in Treatin..
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
07/18/2016 07/19/2016 07/20/2016 07/21/2016 07/22/2016 Date
1.479(c) 1.49(c) 1.53(c) 1.51(c) 1.53(c) Last
94 460 128 085 130 558 82 047 75 399 Volume
+2.36% +0.74% +2.68% -1.31% +1.32% Change
More quotes
Financials ($)
Sales 2016 2,85 M
EBIT 2016 -24,3 M
Net income 2016 -23,6 M
Debt 2016 -
Yield 2016 -
Sales 2017 0,81 M
EBIT 2017 -29,3 M
Net income 2017 -27,1 M
Debt 2017 -
Yield 2017 -
P/E ratio 2016 -
P/E ratio 2017
Capi. / Sales2016 43,1x
Capi. / Sales2017 152x
Capitalization 123 M
More Financials
Company
Pluristem Therapeutics, Inc. is a biotechnology company engages in the provision of cell therapy development.It focuses on cell therapies for the treatment of diseases such as muscle injury, acute radiation syndrome, pulmonary arterial hypertension and others.Its products include PLacental... 
More about the company
Surperformance© ratings of Pluristem Therapeutics Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on PLURISTEM THERAPEUTICS INC
07/20 Pluristem Participates in Radiation Injury Treatment Network Conference Co-sp..
07/11 Pluristem Advances its U.S. FDA Trial in Hematologic Indication
07/07 PLURISTEM THERAPEUTICS INC. : Jobs Growth Spurs Boon to Stocks on Thursday
07/05 PLURISTEM THERAPEUTICS INC. : Stonegate Capital Partners Initiates Coverage on P..
06/22 Pluristem Reports Data Showing PLX-PAD Cells Effective in Treating Duchenne M..
05/31 PLURISTEM THERAPEUTICS INC : Change in Directors or Principal Officers, Submissi..
05/20 PLURISTEM THERAPEUTICS : Completes Enrollment of 150 Patients in Phase II Interm..
05/17 PLURISTEM THERAPEUTICS : Completes Enrollment of 150 Patients in Phase II Interm..
05/16 PLURISTEM THERAPEUTICS : Completes Enrollment of 150 Patients in Phase II Interm..
05/10 PLURISTEM THERAPEUTICS : Reports Third Quarter Fiscal 2016 Financial Highlights ..
More news
Sector news : Biotechnology & Medical Research - NEC
07/21DJAmgen and Allergan Study Finds Biosimilar Comparable to Herceptin
07/12DJAmgen Biosimilar Gets Thumbs-Up From FDA Panel
07/12DJJuno to Resume Clinical Trial of Anticancer Treatment
07/09DJCorrections & Amplifications -- WSJ
07/08DJAMGEN : Theranos Dealt Blow as Holmes Is Banned From -2-
More sector news : Biotechnology & Medical Research - NEC
News from SeekingAlpha
06/22 Midday Gainers / Losers
06/22 HEALTHCARE - TOP 5 GAINERS / LOSERS : 00 am
06/22 PREMARKET GAINERS / LOSERS AS OF 9 : 15 am
06/22 Pluristem's PLX-PAD cells shows positive effect in animal model of muscular d..
06/03 Is It Time To Invest In Stem Cell Biotechs?
Advertisement
Chart PLURISTEM THERAPEUTICS INC
Duration : Period :
Pluristem Therapeutics Inc Technical Analysis Chart | PSTI | US72940R1023 | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 3
Average target price 4,17 $
Spread / Average Target 172%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Zami Aberman Chairman & Chief Executive Officer
Yaky Yanay President, COO, CFO, Secretary & Director
Esther Lukasiewicz-Hagai Vice President-Clinical & Medical Affairs
Mark S. Germain Director
Nachum Rosman Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
PLURISTEM THERAPEUTICS..35.40%123
INCYTE CORPORATION-20.32%16 212
CELLTRION, INC.--.--%10 689
LONZA GROUP AG11.40%9 737
QUINTILES TRANSNATIONA..7.82%8 859
ALKERMES PLC-37.26%7 528
More Results